The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | NICE approves acalabrutinib for CLL in the UK
Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, talks on the NICE approval of the Bruton’s tyrosine kinase inhibitor acalabrutinib for patients with chronic lymphocytic leukemia (CLL) in the UK, commenting on implications for clinical practice. Dr Eyre reports that the biggest impact of the approval will be in the front-line setting. Dr Eyre also highlights the approval of venetoclax in combination with obinutuzumab for patients with CLL.
